Figure 5

Predictive value of the estrogen-related score (ERS) in the high-proliferation group after neoadjuvant letrozole. The dynamic change of proliferation measured by mitosis kinase score (MKS) at baseline, 14 and 90 days in patients with baseline high proliferation treated with neoadjuvant letrozole in the high-ERS (A) and low-ERS (B) groups (red line = clinical response; blue line = non responder; green line = clinical information not available). (C) Box plot describing the proliferation at 14 and 90 days in the high-ERS and low-ERS groups. A comparison between MKS values in different groups was performed by Wilcoxon rank-sum test.